Beijing, China & Fort Lauderdale, Fla., United States:
Eucure (Beijing) Biopharma Co., Ltd. (“Eucure”), a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”), introduced right now that the firm has entered into a worldwide licensing settlement with Syncromune, Inc. (“Syncromune”), a US-based medical stage biopharmaceutical firm, for the growth and commercialization of intratumoral immunotherapies together with Syncromune’s Syncrovax™ know-how.
Under the phrases of the settlement, Syncromune will purchase unique worldwide rights for growth and commercialization of the intratumoral mixture remedy containing Eucure’s YH002, and a number of different lively components as half of the Syncrovax™ remedy. Eucure/Biocytogen reserve all the world rights past Syncrovax™. Pursuant to the settlement, Eucure has the potential to obtain a whole lot of thousands and thousands of US {dollars}, together with an upfront money fee that displays the projected medical worth of the molecules, important growth and regulatory milestone funds, in addition to royalties and different incentives based mostly on the long-term business worth of the Syncrovax™ mixture remedy. Eucure shall be accountable for drug manufacturing and provide, and Syncromune shall be accountable for medical growth and commercialization.
The Syncrovax™ platform is a next-generation customized most cancers remedy being developed to optimize intratumoral immunotherapy for the therapy of metastatic stable tumor cancers. The know-how goals to generate a customized autologous most cancers vaccine utilizing a affected person’s personal most cancers antigens. This new method to combating most cancers is designed to generate a strong anti-cancer response by overcoming the immunosuppressive traits of metastatic cancers and addressing the limitations of present systemic immunotherapies. Syncromune intends to initially develop mixture therapies for metastatic breast, prostate, and lung most cancers, with a strong pipeline aimed toward six further goal cancers.
“YH002 is a co-stimulating molecule for the OX40 target which has shown favorable safety and promising anti-tumor activity against solid tumors,” mentioned Rong Chen, M.D., Ph.D., Chief Executive Officer and Chief Medical Officer of Eucure, and Vice President of Biocytogen. “We are excited to collaborate with Syncromune to realize the potential in intratumoral immunotherapy.”
“We are excited to enter into an exclusive licensing agreement with Eucure/Biocytogen,” mentioned Eamonn Hobbs, President and Chief Executive Officer of Syncromune. “This license settlement is a vital step in the growth of our proprietary Syncrovax™ platform and additional helps Syncromune’s technique to maximize our platform to construct a sustainable most cancers therapeutics firm.”
“We believe the antibodies developed with Biocytogen’s unique platform may provide competitive advantages,” mentioned Charles Link, M.D., Executive Chairman and Chief Medical Officer of Syncromune. “The preclinical data suggests that these second-generation molecules might have best-in-class potential.”
About YH002
YH002 is a recombinant anti-OX40 humanized IgG1 agonistic antibody. The specificity, security, and anti-cancer efficacy of YH002 have been demonstrated in a complete panel of pre-clinical research. The totality of pre-clinical information helps development of YH002 mixture remedy into medical research in grownup topics with domestically superior or metastatic stable tumors. A primary-in-human (FIH), multicenter, open-label, Phase I dose-escalation research is presently underway in Australia to consider the security, tolerability, and pharmacokinetics and decide the MTD/RP2D of YH002 in topics with superior stable malignancies.
About Syncrovax
The Syncrovax platform remedy makes use of a mixture method of tumor activation and focused supply, aiming to synchronize the timing and location of tumor antigen launch with the practical activation of immune cells. To obtain tumor activation, a portion of a goal tumor is lysed to generate immunogenic cell loss of life and the launch of Damage Associated Molecular Patterns (DAMPs) and tumor antigens, altering the tumor microenvironment by creating an in situ vaccine. The second element of the platform, focused supply, entails the intratumoral infusion of a proprietary fixed-dose mixture drug with 4 lively components into the lysed portion of the tumor. This is designed to present immunostimulatory results in the tumor microenvironment and draining lymph nodes, mitigate the most cancers’s potential to block immune responses, and contribute to the activation of antigen presenting cells and cytotoxic T cells. The immune responses triggered by the in situ customized vaccine allow the affected person to vaccinate in opposition to a number of autologous antigens at the identical time. The anti-cancer responses are anticipated to act at the web site of the handled tumor in addition to in metastases all through the physique.
About Eucure
As a wholly owned subsidiary of Biocytogen, Eucure Biopharma focuses on antibody drug remedy for oncology and different indications. Relying on a sturdy medical growth staff with intensive expertise, Eucure Biopharma develops modern medication to meet medical wants for sufferers worldwide. The firm has established a product pipeline for greater than 10 targets, with two in section II MRCTs and two in section I medical trials. For extra info, please go to www.eucure.com/en/index.
About Biocytogen
Biocytogen (HKEX: 02315) is a world biotechnology firm that drives the analysis and growth of novel antibody-based medication with modern applied sciences. Using its proprietary RenMab™ /RenLite® mice platforms for totally human monoclonal and bispecific antibody growth, Biocytogen has built-in its in vivo drug efficacy screening platforms and sturdy medical growth experience to streamline the complete drug growth course of. Biocytogen is enterprise a large-scale venture to develop first-in-class and/or best-in-class antibody medication for greater than 1000 targets, often called Project Integrum. This venture has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with firms round the world, together with a number of partnerships with multinational pharmaceutical firms (MNCs). Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For extra info, please go to http://en.biocytogen.com.cn.
About Syncromune
Syncromune is a privately held, medical stage biopharmaceutical firm devoted to the growth of novel intratumoral immunotherapies for stable tumors. Syncromune is dedicated to bringing life-changing therapies to sufferers with unmet medical wants by combating most cancers in a new approach. The firm is presently growing Syncrovax, a novel platform know-how that makes use of a mixture method to synchronize the timing and location of tumor antigen launch with the practical activation of immune cells. The platform is designed to allow the affected person’s immune system to create a customized autologous vaccine that acknowledges and assaults most cancers all through the physique. The firm’s mission is to be the world chief in optimized intratumoral immuno-oncology drug growth and therapies. Syncromune is headquartered in Fort Lauderdale, FL, USA. For extra info, please go to www.syncromune.com.
View supply model on businesswire.com: https://www.businesswire.com/news/home/20221017005368/en/
